ArticleFluids and barriers of the CNS2025
Gut microbiota modulates CNS barrier function in murine model for multiple sclerosis.
Article in Fluids and barriers of the CNS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease that has been associated with dysfunction of the protective barriers in the central nervous system (CNS), allowing harmful immune cells to enter. Growing evidence implicates gut microbiota dysbiosis in MS pathogenesis, yet its connection to CNS barrier integrity is not fully understood. To address this, we investigated the role of gut microbiota in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by depleting intestinal microbes using a broad-spectrum antibiotic (ABX) regimen. Our results indicate that ABX-mediated gut microbiota depletion was associated with a milder EAE disease course, accompanied by reduced immune cell infiltration and attenuation of EAE-associated loss of barrier integrity. These improvements coincided with preserved expression and localization of tight junction (TJ) proteins, vital for maintaining barrier integrity. While these data support a microbiota-mediated effect, ABX compounds may also exert microbiota-independent immunomodulatory actions. Importantly, although ABX treatment proved beneficial in the inflammatory EAE setting, antibiotics are also known to disrupt immune and barrier homeostasis under steady-state conditions, highlighting their dual and context-dependent nature. To further look into this, we transferred gut microbiota between EAE and healthy mice and observed a microbiota-dependent effect on CNS barrier integrity. Next, treatment with SCFAs partly restored the disrupted CNS barriers and was linked to reduced disease development in EAE. Altogether, our findings suggest that the gut microbiota has dual role in the CNS barriers in MS. These findings align with emerging literature identifying gut-derived signals, particularly under antibiotic perturbation or through microbial metabolites, as critical modulators of neuroimmune homeostasis. Additionally, our results highlight the potential of microbiota-targeted interventions and SCFAs to influence CNS barrier integrity and disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.